Labcorp Holdings LH
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$3.19M (12 inflow days, 8 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 29.3% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 2.39% to 3.13% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| FMR | Mutual Fund | 2026/Q4 | +1,611,797 | 4.2% |
| Goldman Sachs Asset Management, L.P. | Mutual Fund | 2026/Q4 | +555,186 | 1.1% |
| Deka Investment GmbH | Mutual Fund | 2026/Q4 | +284,595 | 0.6% |
| Citadel Advisors LLC | Hedge Fund | 2026/Q4 | +230,053 | 0.3% |
| D. E. Shaw & Co., L.P. | Hedge Fund | 2026/Q4 | +202,062 | 0.3% |
| Invesco Ltd. | Mutual Fund | 2026/Q4 | +199,457 | 0.7% |
| Putnam LLC | Mutual Fund | 2026/Q4 | +187,478 | 0.2% |
| Strategic Advisers LLC | Mutual Fund | 2026/Q4 | +172,885 | 0.3% |
| Gilder Gagnon Howe & Co. LLC | Mutual Fund | 2026/Q4 | +122,278 | 0.2% |
| Aquatic Capital Management LLC | Hedge Fund | 2026/Q4 | +107,950 | 0.1% |
| Invesco Capital Management LLC | Mutual Fund | 2026/Q4 | +100,907 | 1.2% |
| Boone Capital Management LLC | Hedge Fund | 2026/Q4 | +87,551 | 0.1% |
| Qube Research & Technologies Ltd | Mutual Fund | 2026/Q4 | +83,376 | 0.2% |
| JPMorgan Chase & Co. | Public Company | 2026/Q4 | +77,321 | 0.4% |
| Holocene Advisors, LP | Hedge Fund | 2026/Q4 | +74,856 | 0.1% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 9 Nov 2026 | Brian Caveney | Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer | Open Market Disposition | -2,000 | $372.04 | 34,562 |
| 3 Nov 2026 | Megan Bailey | Former Executive VP and President of Central Laboratory Services & International Labcorp | Intent to Sell (Form 144) | -3,035 | $361.16 | – |
| 2 Nov 2026 | Bryan Vaughn | Executive VP & President of Diagnostics | Automatic Disposition | -306 | $353.70 | 6,845 |
| 1 Nov 2026 | Akinbolade Oyegunwa | Executive VP and Chief Information & Technology Officer | Derivative Exercise and Sale | -118 | $355.59 | 5,316 |
| 1 Nov 2026 | Bryan Vaughn | Executive VP & President of Diagnostics | Derivative Exercise and Sale | -194 | $355.59 | 7,151 |
| 31 Oct 2026 | Akinbolade Oyegunwa | Executive VP and Chief Information & Technology Officer | Derivative Exercise and Retained | +252 | – | 5,316 |
| 31 Oct 2026 | Bryan Vaughn | Executive VP & President of Diagnostics | Derivative Exercise and Retained | +306 | – | 7,151 |
| 29 Oct 2026 | Richelle Parham | Independent Director | Open Market Disposition | -1,078 | $361.22 | 2,288 |
| 31 Aug 2026 | Brian Caveney | Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer | Other Derivative Acquisition | +3,000 | – | 7,170 |
| 31 Aug 2026 | Akinbolade Oyegunwa | Executive VP and Chief Information & Technology Officer | Other Derivative Acquisition | +750 | – | 2,940 |
| 31 Aug 2026 | Jonathan Meltzer | Chief Operating Officer | Other Derivative Acquisition | +900 | – | 3,594 |
| 31 Aug 2026 | Bryan Vaughn | Executive VP & President of Diagnostics | Other Derivative Acquisition | +1,500 | – | 5,204 |
| 16 Aug 2026 | Kerrii Anderson | Independent Director | Automatic Disposition | -3,000 | $318.02 | 6,851 |
| 10 Aug 2026 | Adam Schechter | Chairperson & CEO | Automatic Disposition | -4,669 | $320.37 | 102,565 |
| 3 Aug 2026 | Amy Summy | Executive VP, Chief Marketing Officer & Consumer Health Lead | Open Market Disposition | -924 | $306.74 | 6,956 |
| 2 Aug 2026 | Peter Wilkinson | Chief Accounting Officer | Open Market Disposition | -82 | $309.22 | 1,770 |
| 2 Aug 2026 | Peter Wilkinson | Chief Accounting Officer | Derivative Exercise and Sale | -1,338 | $309.23 | 1,770 |
| 1 Jul 2026 | Kathryn Kyle | Executive Vice President | Intent to Sell (Form 144) | -92 | $286.19 | – |
| 1 Jul 2026 | Bryan Vaughn | Executive VP & President of Diagnostics | Intent to Sell (Form 144) | -234 | $286.19 | – |
| 1 Jul 2026 | Kathryn Kyle | Executive Vice President | Derivative Exercise and Sale | -165 | $286.19 | 3,904 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 2,544,414 | 3.1% | 3.0 |
| 15 Oct 2026 | 2,557,656 | 3.2% | 4.2 |
| 30 Sep 2026 | 2,684,363 | 3.3% | 3.0 |
| 15 Sep 2026 | 2,448,617 | 3.0% | 3.3 |
| 31 Aug 2026 | 2,103,302 | 2.6% | 3.2 |
| 14 Aug 2026 | 1,938,163 | 2.4% | 3.8 |
No comments yet — be the first to weigh in on LH.
Sign in to join the discussion.